The aim of the present study is to enhance the anticancer and biocompatibility performance of TiO2 and ZnO nanoparticles, and, ZnO-TiO2 and ZnO-TiO2/reduced graphene oxide nanocomposites, against two types of human cancer (HCT116) and normal (HUVCE) cells.